GSK (GSK) Seals $10.6 Billion Nuvalent Acquisition In Largest Deal For Cancer Portfolio In Over A Decade

British drugmaker GSK has agreed to acquire U.S.-listed oncology specialist Nuvalent in an all-cash deal valued at $10.6 billion. The transaction values Boston-based Nuvalent at approximately $124 per share, representing a 40% premium to its last closing price. Net of cash acquired, GSK’s aggregate investment is estimated at $9.4 billion, with the deal primarily funded…

Read More

An El Niño Inflation Storm Threatens Portfolios As Climate Shock Looms Over Commodity Markets

Investors betting that U.S. inflation will ease once the Iran conflict ends and energy prices fall may be badly miscalculating their exposure to risk. A powerful El Niño weather pattern is expected to pick up where geopolitical disruptions leave off, threatening to drive global commodity prices significantly higher in the months ahead. Analysts at Marex,…

Read More